Key result
Lansoprazole provided a significantly higher percentage of 24-hour heartburn-free days (median 81.4%) compared to ranitidine (66.6%), step-up (66.9%), and step-down therapy (73.6%) (p<0.01).
Why the study?
Does lansoprazole or step-up/step-down therapy improve heartburn severity and heartburn-free days compared to ranitidine in adults with heartburn?
Population
593 adults with heartburn
Comparison
Lansoprazole 30 mg once daily for 20 weeks, or… vs Ranitidine 150 mg b.i.d. for 20 weeks
Design
RCT, randomized to one of four groups, double-blind
Follow-up
20 weeks
Authors
Loading...
Supports continuous PPI-first strategy for heartburn; confirms superiority over ranitidine and step-up/down regimens in RCTs.
RCT (n=593)
Double-blind
randomized
Yes
Does lansoprazole or step-up/step-down therapy improve heartburn severity and heartburn-free days compared to ranitidine in adults with heartburn?
Absolute Event Rate: 81.4% vs 66.6%
p-value: p=<0.01
Continuous proton pump inhibitor therapy with lansoprazole provides more consistent heartburn relief than H2-receptor antagonist therapy or step-up/step-down strategies.
Howden et al. (2001) conducted an RCT in Heartburn (n=593). Lansoprazole vs. Ranitidine, step-up therapy, or step-down therapy was evaluated on Percentage of 24-h heartburn-free days (p=<0.01). Lansoprazole provided a significantly higher percentage of 24-hour heartburn-free days (median 81.4%) compared to ranitidine (66.6%), step-up (66.9%), and step-down therapy (73.6%) (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: